NASDAQ:REGN

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)

Retrieved on: 
Thursday, April 18, 2024
DOJ, False Claims Act, News, Medicare, Private investigator

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN ).

Key Points: 
  • NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN ).
  • The investigation concerns whether Regeneron and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On April 10, 2024, the U.S. Department of Justice (“DOJ”) issued a press release announcing its complaint filed against Regeneron under the False Claims Act.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, April 18, 2024
P.C, DOJ, Telephone, Medicare, Pharmaceutical industry

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) on behalf of Regeneron stockholders.

Key Points: 
  • NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) on behalf of Regeneron stockholders.
  • Our investigation concerns whether Regeneron has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Regeneron is the subject of a DOJ lawsuit filed on April 10, 2024.
  • The lawsuit accuses Regeneron of failing to report millions of dollars in discounts given to drug distributors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Retrieved on: 
Thursday, April 11, 2024
Suite, Ethics, Regeneron Pharmaceuticals, DOJ, Medicare

LOS ANGELES, April 11, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN ) for violations of the securities laws.

Key Points: 
  • LOS ANGELES, April 11, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • Regeneron is the subject of a DOJ lawsuit filed on April 10, 2024.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

Retrieved on: 
Wednesday, April 17, 2024
Class Action Lawsuit, Professional Services, Legal, State, News, Accusative case, Regeneron Pharmaceuticals, Suite, Justice minister, Law, Complaint, Medicare

The Law Offices of Frank R. Cruz announces an investigation of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN ) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN ) on behalf of investors concerning the Company’s possible violations of federal securities laws.
  • If you are a shareholder who suffered a loss, click here to participate.
  • If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm

Retrieved on: 
Friday, March 22, 2024
Regeneron Pharmaceuticals, PLLC, Human, REGN

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) breached their fiduciary duties to shareholders.

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) breached their fiduciary duties to shareholders.
  • Kuehn Law pays all case costs and does not charge its investor clients.
  • Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
  • As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets.

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

Retrieved on: 
Wednesday, March 13, 2024
Lung cancer, Pollination, Bee, Metabolism, Culture, Gene, Algorithm, Alzheimer's disease, National Medal, Growth, Aditi, Gene expression, Survival, Cell, Bone marrow, Trustee, School, Brain, Research, Science News, RET, Highlands Ranch, Colorado, Death, Macrophage, ARD International Music Competition, Society, Thought, Student, Nobel Prize, STEM, CO, Cancer, MYC, ChatGPT, Machine learning, Society for Science, Liver, STS, Pharmaceutical industry

TARRYTOWN, N.Y. and WASHINGTON, March 12, 2024 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Achyuta Rajaram, 17, of Exeter, NH, won the top award in the Regeneron Science Talent Search (STS) 2024, America's oldest and most prestigious science and math competition for high school seniors.

Key Points: 
  • This knowledge sheds light on what these algorithms are "thinking," which can help make them more effective, fair and safe.
  • "Congratulations to the winners of this year's Regeneron Science Talent Search," said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News.
  • The Regeneron Science Talent Search empowers young people who are passionate about innovation and using scientific discovery to contribute to improving our world.
  • In total, Regeneron awarded $3.1 million in prizes through the Regeneron Science Talent Search 2024, including $2,000 to each of the top 300 scholars and their schools.

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

Retrieved on: 
Wednesday, January 24, 2024
Entrepreneurship, Student, Neuroscience, Regeneron Pharmaceuticals, Biochemistry, Materials science, Physics, Research, Environmental science, Mathematics, Animal, Nobel Prize, Social, Knowledge, Chemistry, School, Society, Molecular biology, Medicine, Anxiety, Botany, DSM-IV codes, Creativity, College of Engineering (KNUST), Computational biology, Society for Science, Science News

TARRYTOWN, N.Y. and WASHINGTON, Jan. 24, 2024 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year's Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.

Key Points: 
  • Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM)
    TARRYTOWN, N.Y. and WASHINGTON, Jan. 24, 2024 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year's Regeneron Science Talent Search , the nation's oldest and most prestigious science and math competition for high school seniors.
  • "We applaud this dynamic group of Regeneron Science Talent Search finalists on their impressive achievement," said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News.
  • The top 10 Regeneron Science Talent Search 2024 winners will be announced during an awards ceremony on March 12, streamed live from Washington D.C.
  • In total, more than $3 million in awards will be distributed throughout the Regeneron Science Talent Search.

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

Retrieved on: 
Tuesday, October 3, 2023
CRISPR, NTLA, Senior, Regeneron Pharmaceuticals, Gene editing, Cell, Antibody, AAV, Intellia Therapeutics, Facial muscles, Liver, Vaccine, Research

This builds on the success of the companies’ existing collaboration and continues to combine both companies’ deep biology and technology expertise.

Key Points: 
  • This builds on the success of the companies’ existing collaboration and continues to combine both companies’ deep biology and technology expertise.
  • “We are excited to expand our successful collaboration with Regeneron to now accelerate the development of CRISPR-based therapies outside of the liver for the treatment of neurological and muscular diseases with significant unmet need,” said Intellia President and Chief Executive Officer John Leonard, M.D.
  • “At Intellia, we are continuously innovating our editing and delivery solutions to realize the full potential of CRISPR gene editing as a new therapeutic modality.
  • Intellia will lead the design of the editing methodology and Regeneron will lead the design of the targeted viral vector delivery approach.

Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

Retrieved on: 
Monday, September 25, 2023
Diet, Lipidology, Department of Medicine – University of Pamplona, ANGPTL3, Patient, Disease, Ageing, Health Canada, Pharmaceutical industry, Evinacumab

Evkeeza® was approved by Health Canada as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH) and will be commercially available in Canada effective 25-November-2023.

Key Points: 
  • Evkeeza® was approved by Health Canada as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia (HoFH) and will be commercially available in Canada effective 25-November-2023.
  • Evkeeza is a first-of-its-kind treatment for HoFH and is the first monoclonal antibody inhibiting the angiopoietin-like 3 protein (ANGPTL3).
  • The treatment is now available to prescribe for patients with HoFH in Canada.
  • “The approval and launch of Evkeeza in Canada for the treatment of homozygous familial hypercholesterolemia exemplifies our commitment to bring innovative therapies for people living with rare and ultrarare genetic diseases,” said Monty Keast, Vice President and General Manager at Ultragenyx Canada.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - DBT

Retrieved on: 
Thursday, August 31, 2023
Agreement, CVR, Tripura Merger Agreement, Campbell Soup Company, Brodsky, CPB, REGN, Zebra, NYSE, Acquisition, CTG, Therapy, Security (finance), Regeneron Pharmaceuticals, Sovo, Acer

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the Agreement, Acer will be acquired by Zevra Therapeutics, Inc. (“Zevra”) (Nasdaq - ZVRA).
  • At closing, Zevra would issue 0.121 of a share of Zevra’s common stock in respect of each share of Acer’s common stock.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.